Overview Executive Committee Supervisory Board Locations
Overview Satraplatin Kinase Inhibitors
Stock Key Figures Financial Reports SEC Filings Corporate Governance Analyst Coverage Shareholder´s Meeting Webcasts Information Request
Press Releases Virtual Press Kit Contact Information
Working for GPC Biotech Germany USA
GPC Biotech To Re-Schedule Annual Shareholders’ Meeting GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel Webcast of Presentation at Piper Jaffray Europe Conference in London GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes GPC Biotech to Present at Two Upcoming Conferences: 7th Annual Needham Biotechnology & Medical Technology Conference in New York and Piper Jaffray Europe Conference in London Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting GPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual Meeting GPC Biotech Reports Financial Results for First Quarter 2008 GPC Biotech Schedules Conference Call on May 15th to Discuss First Quarter 2008 Financial Results Annual Report 2007 GPC Biotech Reports Financial Results for Fiscal Year 2007 GPC Biotech to Present at Cowen and Company 28th Annual Health Care Conference in Boston GPC Biotech to Hold Conference Call on March 27, 2008 to Discuss Year-End 2007 Financial Results GPC Biotech Announces Corporate Restructuring and Provides Pipeline Update GPC Biotech to Provide Update on Research and Development Programs at JPMorgan 26th Annual Healthcare Conference in San Francisco GPC Biotech to Present at JPMorgan 26th Annual Healthcare Conference in San Francisco GPC Biotech Appoints Torsten Hombeck as Chief Financial Officer GPC Biotech to Present at 19th Annual Piper Jaffray Health Care Conference in New York GPC Biotech Announces Corporate Restructuring GPC Biotech Reports Financial Results for Third Quarter and First Nine Months of 2007 GPC Biotech Announces Favorable Ruling in Arbitration with Spectrum Pharmaceuticals GPC Biotech Meeting and Conference Call on Third Quarter 2007 Results Scheduled for November 8th GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial GPC Biotech to Present at UBS Global Life Sciences Conference in New York GPC Biotech Announces Restructuring GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2007 GPC Biotech Schedules Conference Call on August 8th to Discuss First Half 2007 Financial Results GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated Approval GPC Biotech AG Named in Purported Class Action Lawsuit in the United States FDA Oncologic Drugs Advisory Committee Recommends that FDA Wait for Overall Survival Results from Satraplatin Phase 3 Trial GPC Biotech Schedules Conference Call on July 25 to Discuss Oncologic Drugs Advisory Committee (ODAC) Recommendation on Satraplatin GPC Biotech Announces that Partner Pharmion Submits European Marketing Application for Satraplatin GPC Biotech Announces Partnering Agreement for Satraplatin for Japan with Yakult GPC Biotech to Present at Second Annual Piper Jaffray London Health Care Conference GPC Biotech to Present at Two Upcoming Conferences: Goldman Sachs 28th Annual Global Healthcare Conference in California and 6th Annual Needham Biotechnology & Medical Technology Conference in New York Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting GPC Biotech to Host Investor Event in Chicago on June 4th during ASCO Annual Meeting GPC Biotech Announces Election of Donald Soltysiak to Supervisory Board Live Webcast of Speech at Annual General Meeting of GPC Biotech AG on May 25, 2007 at approx. 10 AM CET Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association GPC Biotech’s Satraplatin NDA to be Reviewed by ODAC Panel on July 24, 2007 GPC Biotech Reports Financial Results for the First Quarter of 2007 GPC Biotech to Present at Two Upcoming Conferences: Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo and Citigroup Healthcare Conference in New York City GPC Biotech Schedules Conference Call on May 15th to Discuss First Quarter 2007 Financial Results GPC Biotech Consolidates Drug Discovery Activities FDA Accepts GPC Biotech’s Satraplatin NDA for Filing and Grants Priority Review Status Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress GPC Biotech to Present at Lehman Brothers Tenth Annual Global Healthcare Conference in Florida GPC Biotech Reports Financial Results for Fiscal Year 2006 GPC Biotech Meeting and Conference Call on Business Results for Fiscal Year 2006 Scheduled for March 15 Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients GPC Biotech Launches Expanded Access Program for Oncology Drug Candidate Satraplatin in the U.S. GPC Biotech Schedules Conference Call to Discuss Results from the Satraplatin Phase 3 Trial Being Presented at the ASCO Prostate Cancer Symposium in Orlando, Florida GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin GPC Biotech Raises € 33.6 Million (~$43.7) in Private Placement GPC Biotech Responds to Arbitration Claim by Spectrum Pharmaceuticals GPC Biotech Schedules Conference Call on July 25 to Discuss Oncologic Drugs Advisory Committee (ODAC) Recommendation on Satraplatin